Skip to main content

Bristol-Myers Squibb Company (BMY)

NYSE: BMY · IEX Real-Time Price · USD
60.20
-0.03 (-0.05%)
After-hours:Sep 24, 2021 7:59 PM EDT
60.23
-0.40 (-0.66%)
At close: Sep 24, 4:00 PM
Market Cap133.84B
Revenue (ttm)44.38B
Net Income (ttm)-5.08B
Shares Out2.23B
EPS (ttm)-2.26
PE Ration/a
Forward PE7.59
Dividend$1.92 (3.19%)
Ex-Dividend DateSep 30, 2021
Volume9,541,676
Open60.55
Previous Close60.63
Day's Range60.17 - 61.10
52-Week Range55.46 - 69.75
Beta0.59
AnalystsBuy
Price Target80.06 (+32.9%)
Est. Earnings DateOct 27, 2021

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and ps...

IndustryPharmaceuticals
Founded1887
CEOGiovanni Caforio
Employees30,250
Stock ExchangeNYSE
Ticker SymbolBMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 80.06, which is an increase of 32.92% from the latest price.

Price Target
$80.06
(32.92% upside)
Analyst Consensus: Buy

News

Is Bristol Myers Squibb Stock a Buy?

Maybe, but not if you're looking for major growth over the short term.

1 hour ago - The Motley Fool

5 Brand-Name Stocks to Buy Hand Over Fist if the Market Is Tumbling

Market sell-offs are perfectly normal and an opportune time to invest in great companies at a discount.

Other symbols:AVGOCRMHDMA
3 days ago - The Motley Fool

3 Cheap Healthcare Stocks to Buy Right Now

The Baby Boomers are getting older, which means investors should consider adding undervalued healthcare stocks to their portfolio. The post 3 Cheap Healthcare Stocks to Buy Right Now appeared first on I...

Other symbols:IRWDNUS
4 days ago - InvestorPlace

Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review

Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.

5 days ago - Zacks Investment Research

Bristol Myers Squibb (BMY) Stock Moves -1.32%: What You Should Know

Bristol Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.32% move from the prior day.

5 days ago - Zacks Investment Research

Big Pharma Stocks Hit Hard by Drug Price Proposals

Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...

Other symbols:JNJLLYMRKPFE
5 days ago - GuruFocus

Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.

5 days ago - Zacks Investment Research

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking A...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BLA--U.S. FDA Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination...

6 days ago - Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Nega...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal....

1 week ago - Business Wire

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.23, marking a -1.24% move from the previous day.

1 week ago - Zacks Investment Research

Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC)....

1 week ago - Benzinga

7 Stocks to Buy to Invest Like Jim Cramer

Jim Cramer has done an excellent job exciting investors about stocks to buy. That said, let's look at some of his favorite picks.

Other symbols:AAPLCOSTCRMFHONNVDA
1 week ago - InvestorPlace

Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overa...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO21--Five-Year Data from CheckMate -214 Show Opdivo Plus Yervoy Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial.....

1 week ago - Business Wire

Investing in These 2 Top Stocks Could Make You Richer Over the Next 10 Years

Don't miss out on these two thriving businesses.

Other symbols:SHOP
1 week ago - The Motley Fool

7 Stocks to Buy if the Market Crashes in September

Market crashes often present lucrative investment opportunities for investors in top stocks to buy at cheaper prices. Watch these seven.

Other symbols:CRMCRWDGTBIFHDNEETRUP
1 week ago - InvestorPlace

Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting

Bristol Myers Squibb & Co (NYSE: BMY) announced three-year data from the CheckMate -743 trial demonstrating a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipil...

1 week ago - Benzinga

According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact ...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #cancer--According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment...

1 week ago - Business Wire

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemothe...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO21--Opdivo + Yervoy Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural....

1 week ago - Business Wire

Bristol Myers Squibb (BMY) Stock Moves -0.71%: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $63.13, marking a -0.71% move from the previous day.

2 weeks ago - Zacks Investment Research

Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cardio--BMS Shares Research Supporting Correlation between NYHA class and Mortality in Obstructive Hypertrophic Cardiomyopathy

2 weeks ago - Business Wire

7 Stocks To Buy To Bet on Underappreciated CEOs

We hear plenty of stories about overpaid CEOs. Here are seven stocks to buy whose CEOs aren't but still manage to deliver for shareholders.

2 weeks ago - InvestorPlace

Bristol Myers Squibb Announces Dividend

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Dividend

2 weeks ago - Business Wire

BOLT Enters Into a Collaboration Agreement With Bristol Myers

BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.

2 weeks ago - Zacks Investment Research

Final Trades: Bristol Myers, Marathon Petroleum, Zoetis & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols:MPCZTSNYCB
2 weeks ago - CNBC Television

Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021

2 weeks ago - Business Wire